Literature DB >> 32247520

Medication-related osteonecrosis of the jaws and quality of life: review and structured analysis.

J Murphy1, C J Mannion2.   

Abstract

Medication-related osteonecrosis of the jaws (MRONJ) is a rare complication of bisphosphonates, or antiresorptive or antiangiogenic medication. Treatment is difficult as the bone has a poor capacity for healing, and further progression after surgery can occur. Quality of life (QoL) in patients with MRONJ has not been well documented. The aim of this study therefore was to identify and analyse data on QoL in this group of patients. Eight studies that were identified through a systematic search of the literature were qualitatively analysed. Overall, data on QoL are lacking and are complicated by concurrent disease such as cancer. Patients generally have a poor QoL because of MRONJ, and multiple oral-specific complaints including pain and problems with speech. Development of a questionnaire specific to patients with MRONJ would help improve the specificity of the data collected. Prospective questionnaires before and after intervention, including information on stage and comorbidities, would guide future treatment strategies.
Copyright © 2020 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MRONJ; bisphosphonates; quality of life; review

Mesh:

Substances:

Year:  2020        PMID: 32247520     DOI: 10.1016/j.bjoms.2020.03.010

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  5 in total

1.  Quality of life in cancer patients with or without medication-related osteonecrosis of the jaw.

Authors:  Sara de Cassia Tornier; Fernanda Joly Macedo; Laurindo Moacir Sassi; Juliana Lucena Schussel
Journal:  Support Care Cancer       Date:  2021-05-10       Impact factor: 3.603

Review 2.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

3.  Does Medication-Related Osteonecrosis of the Jaw Influence the Quality of Life of Cancer Patients?

Authors:  Gianluca Tenore; Ahmed Mohsen; Antonella Francesca Rossi; Gaspare Palaia; Federica Rocchetti; Andrea Cassoni; Valentino Valentini; Livia Ottolenghi; Antonella Polimeni; Umberto Romeo
Journal:  Biomedicines       Date:  2020-04-24

4.  Macrophage miR-149-5p induction is a key driver and therapeutic target for BRONJ.

Authors:  Xin Shen; Weiwen Zhu; Ping Zhang; Yu Fu; Jie Cheng; Laikui Liu; Rongyao Xu; Hongbing Jiang
Journal:  JCI Insight       Date:  2022-08-22

5.  Patients' quality of life improves after surgical intervention of stage III medication-related osteonecrosis of the jaw.

Authors:  Stefan Moll; Steffen Mueller; Johannes K Meier; Torsten E Reichert; Tobias Ettl; Christoph Klingelhöffer
Journal:  Oral Maxillofac Surg       Date:  2020-11-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.